---
layout: post
title: "港A两地CXO板块集体走强 机构称已处于估值底部具配备价值"
date: 2022-02-14 11:11:58 +0800
categories: gelonghui
tags: 格隆汇新闻
---
<p>A股<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>涨停，<span id="Info.116.03347"><a href="http://quote.eastmoney.com/unify/r/116.03347" class="keytip" data-code="116,03347">泰格医药</a></span>涨超5%，<span id="Info.116.03759"><a href="http://quote.eastmoney.com/unify/r/116.03759" class="keytip" data-code="116,03759">康龙化成</a></span>、<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>和<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>涨超4%，<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>涨近4%；港股<span web="1" href="http://quote.eastmoney.com/unify/r/116.03347" class="em_stock_key_common" data-code="116,03347">泰格医药</span>涨超7%，金斯瑞涨超6%，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>、<span id="Info.116.06127"><a href="http://quote.eastmoney.com/unify/r/116.06127" class="keytip" data-code="116,06127">昭衍新药</a></span>涨超2%，<span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>和<span web="1" href="http://quote.eastmoney.com/unify/r/116.03759" class="em_stock_key_common" data-code="116,03759">康龙化成</span>涨近1%。</p>
 <p><span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>最新<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>称：2022年国内主流CXO公司平均市盈率为41倍，PEG均值0.93，与国外CXO公司相比，A股CXO估值已经大幅消化。国内龙头CXO公司已与美国龙头药企合作多年，且承接大批新冠药物订单，若美国药企更换CXO服务商需付出高成本，承担高风险，所以仍然认为国内CXO龙头公司被列入实体清单可能性不高。<span web="1" href="http://quote.eastmoney.com/unify/r/116.02269" class="em_stock_key_common" data-code="116,02269">药明生物</span>被列入UVL对公司及行业影响也极为有限，且有望未来数月内移出清单。回顾2021年全球及中国药企研发投入、新药管线数量、医疗健康产业融资额与融资数，我们认为CXO需求不减，仍具备充足动能。国内CXO公司2021年<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>预告也展现出CXO业绩能见度从未改变，我们认为具备配备价值。</p><p class="em_media">（文章来源：格隆汇）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202202142275460869>

[返回格隆汇新闻](//finews.withounder.com/category/gelonghui.html)｜[返回首页](//finews.withounder.com/)